<DOC>
	<DOCNO>NCT00080197</DOCNO>
	<brief_summary>The purpose study determine E7070 efficacious , safe , tolerable treatment patient metastatic breast cancer fail , could tolerate , prior treatment anthracycline , taxane , capecitabine .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety , Tolerability E7070 Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients must female , Patients must histologically cytologically confirm metastatic breast cancer , Patients must either tumor resistant/refractory chemotherapy anthracycline , taxane , capecitabine , appropriate Herceptin therapy , tumor treat agent due patient ’ treatment toxicity ; therefore , patient must receive 2 prior chemotherapy 3 prior chemotherapy metastatic setting , Patients must least one unidimensionally measurable lesion accord RECIST criterion least one site irradiate , Patients must age &gt; = 18 year , Patients must Karnofsky Performance Status &gt; = 70 % , Patients must life expectancy &gt; = 3 month , Patients must adequate renal function evidence serum creatinine &lt; = 1.5 mg/dL , &gt; 1.5 &lt; = 1.8 mg/dL , creatinine clearance &gt; = 45 mL/min , Patients must adequate bone marrow function evidence absolute neutrophil count &gt; = 1.5 x 109/L , hemoglobin &gt; = 9.0 g/dL , platelet count &gt; = 100 x 109/L , Patients must adequate liver function evidence bilirubin &lt; = 1.5 time upper limit normal ( ULN ) ; alkaline phosphatase &lt; = 3 time ULN alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; = 3 time ULN , unless relate liver metastasis , case &lt; = 5 x ULN , Patients must serum electrolyte include calcium ( correct albumin ) , magnesium , potassium ( correct ) within normal limit , Patients must willing able complete FACTB questionnaire , Patients must willing able comply study protocol duration study , Patients must give write informed consent prior study specific screen procedure understand patient may withdraw consent time without prejudice . Patients must metastatic disease completely surgically resect , Patients receive adjuvant taxane must experience disease progression within 12 month begin therapy , Patients must receive chemotherapy , hormonal therapy , Herceptin within 2 week E7070 treatment start must recover chemotherapyrelated therapyrelated toxicity study entry , Patients must receive investigational drug include immunotherapy , gene therapy , biologic therapy ; antineoplastic therapy ; radiation therapy ( require palliation bone pain chest ulceration ) within 2 week E7070 treatment , Patients must receive prior treatment Mitomycin C nitrosoureas , Patients must undergo high dose chemotherapy hematopoietic stem cell rescue , Patients must untreated brain metastasis ( Patients treat central nervous system ( CNS ) metastases must asymptomatic radiologically stable [ receive radiation ] must receive steroid 4 week prior entry . Patients without know CNS metastases symptomatic CNS metastasis must evaluate CT scan MRI scan prior E7070 treatment . ) , Patients must major surgery without full recovery within 4 week E7070 treatment start , Patients must pulmonary lymphatic involvement result pulmonary dysfunction require active treatment , include use oxygen , Patients must leptomeningeal metastasis , Patients must evidence clinically relevant ascites pleural effusion require one isolated paracentesis pleurocentesis per month prior study start , Patients must expect require one isolated paracentesis pleurocentesis per month study treatment clinically relevant ascites pleural effusion , Patients must pregnant breastfeeding must practice adequate contraception surgically sterile , Patients must severe medically uncontrolled intercurrent illness/infection , Patients must unstable angina myocardial infarction past 6 month , Patients must serious cardiac arrhythmia symptomatic congestive heart failure &gt; = Grade II ( NYHA classification ) , Patients must history prolong QT , QTc &gt; 470 m ( Bazett ’ correction ) entry , history torsade de pointes , Patients must recent history ( &lt; = 12 month ) active chronic viral hepatitis , Patients must organ allograft , Patients must know history HIV positivity , Patients must history hypersensitivity sulfonamide , Patients must history uncontrolled seizure , Patients must prior malignancy , carcinoma situ cervix nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat &gt; = 5 year previously subsequent evidence recurrence , Patients must significant disease disorder , Investigator ’ opinion , would exclude patient study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Cancer Breast</keyword>
</DOC>